STUDresearch · Non-peptide
Dasatinib + Quercetin
Also known as
D+Q · D plus Q senolytic · Sprycel + quercetin
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Some talk
Systemic
Oral
Longevity / cellular
Systemic intermittent senolytic drug+polyphenol combo.
What people say
D+Q is an experimental oral senolytic pairing of prescription dasatinib with quercetin. Its early human studies are small and disease-specific; it is not an approved longevity treatment.
Doses people talk about
Rows preserve both components, shared days and spacing while separating small-study protocols from copied community calendars. There is no approved longevity dose: dasatinib is an oncology tyrosine-kinase inhibitor, and intermittent community use does not erase its drug interactions or serious labeled toxicities. Community repeat spacing: Often monthly or quarterly pulses. Informal calendars vary and are not a validated healthy-user schedule.
How it may feel
Inspected oral-pulse accounts ranged from no noticeable effect or slight one-day fatigue to nausea, feverishness, headache, brain fog and several days of fatigue. Multi-agent use and expectation make the claimed cause uncertain.
Small-study pulse amountsDasatinib ~100 mg/day + quercetin ~1000–1250 mg/day for 2–3 consecutive days
Disease-specific studies and community copies vary in quercetin amount, formulation and repeat calendar; this is descriptive, not a regimen endorsement.
Half-life & effect duration
- Half-life in the body
- Dasatinib componentAbout 3–5 hours
- Quercetin · oral capsule studyAbout 3.5 hours
- Quercetin · food / glycoside metabolitesAbout 11 hours
- Felt duration people report
- Shorter accountsNo noticeable effect or about 1 day of mild fatigue
- Longer accountsNausea, feverishness, fatigue or brain fog for several days; one report still symptomatic at day 5
Cycles people discuss
The recurring pattern is a 2–3-day oral pulse followed by weeks or months off. Small studies used one three-day course or weekly three-day clusters; community calendars also vary monthly, every other month or quarterly.
Timing
Both components are discussed on the same brief block of on-days, followed by longer gaps; the retained combination notes do not establish one preferred morning or evening slot. Practical discussion considers tolerability, training and sleep rather than a universal clock-time rule.
Stacks
Dasatinib and quercetin are already a two-agent combination. Fisetin is discussed as an alternative or add-on, but larger longevity stacks make both benefits and adverse effects harder to attribute.
Watch for
Dasatinib toxicities: Serious drug — cytopenias, fluid retention, etc. in medical use.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The dasatinib tablet component has a mean terminal half-life of about 3–5 hours after oral clinical doses.
The current dasatinib label reports oral Tmax from 0.5 to 6 hours and mean terminal half-life of 3–5 hours. D+Q has no single blended elimination clock.
The label describes dasatinib, not quercetin or the combined senolytic effect. Quercetin formulations and analytes differ, and outcome or biopsy timing cannot substitute for parent-compound pharmacokinetics.
- DailyMed — Dasatinib tablets full prescribing information (opens in a new tab)Clinical Pharmacology section: oral Tmax 0.5–6 hours, mean terminal half-life 3–5 hours, CYP3A4 metabolism, food and interaction effects.Oncology label for dasatinib alone; it does not establish quercetin pharmacokinetics or a longevity indication.
- Hickson et al. — Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (opens in a new tab)Open-label Phase 1 report: nine adults with diabetic kidney disease received oral dasatinib 100 mg plus quercetin 1000 mg for three days; tissue and blood endpoints were collected 11 days after completion.Very small, open-label, disease-specific biomarker study; no healthy-longevity efficacy or felt-duration estimate.
Felt duration people report
Inspected accounts do not establish one felt-duration window: reports span no noticeable effect, about one day of slight fatigue, acute nausea or feverishness, and fatigue or brain fog continuing for several days.
One Longecity author described mainly treatment-day fatigue after changing a confounded multi-agent pulse. Rapamycin.news included a long-term user reporting no obvious effect and another attributing benefits amid multiple agents. A separate one-dose account described symptoms continuing five days later.
These are unverified self-reports with different quercetin forms, co-agents, calendars and health contexts. Same-author follow-ups improve chronology but do not measure clearance or prove senescent-cell death caused the symptoms.
- Longecity — Dasatinib + Quercetin: please share dosing info (opens in a new tab)Posts #4 and #6 by Fafner55: repeated dasatinib/quercetin with fisetin and honokiol; slight fatigue for about a day at the stated combination, with higher phytochemical amounts previously reduced because of fatigue and an unmeasured liver concern. Fever, diarrhea, nausea and skin sloughing were monitored, not all claimed as experienced at that combination.Unverified products and identity, multiple simultaneous agents, self-selected reporting and no objective adjudication; protocol arithmetic was not adopted as guidance.
- Rapamycin.news — Has anyone used Dasatinib + Quercetin as a senolytic? (opens in a new tab)First-person posts and same-author follow-ups include multi-year intermittent D+Q with no noticeable effect and a separate multi-agent longevity stack credited with arthritis or inflammation improvement while declining attempts to isolate the agent.Self-reported regimens, outcomes and product identity; strong co-intervention and attribution confounding.
- Age Reversal Forum — Details of Dasatinib / Quercetin study (opens in a new tab)One author described mild nausea several hours after an oral D+Q dose, then low fever, chills, headache and malaise; a five-day follow-up still reported fatigue and brain fog.Single uncontrolled self-report with a self-selected amount, no product verification or causal adjudication; the author’s dosing calculation was not reproduced as guidance.
Other context in this card
- Nambiar et al. — Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I randomized pilot trial on feasibility and tolerability (opens in a new tab)Abstract: 12 participants, six per arm, received D 100 mg plus Q 1250 mg or placebo for three consecutive days per week across three weeks; feasibility and tolerability were central.Tiny condition-specific pilot, not a general efficacy or healthy-user safety study; abstract review does not resolve all formulation details.
What people say
- Healthspan narrative: Dasatinib + Quercetin is discussed for aging markers, energy, or recovery more than acute gym pumps. forum
- Slow endpoints, short exposure: Legacy self-logs judge claimed changes over months, not just days, and attribution remains weak. Inspected human D+Q studies use short oral pulses with tissue or outcome checks later; months of evaluation do not mean continuous dosing. anecdotetrial
- Stack noise: Frequently combined with multi-agent longevity stacks that destroy attribution. forum
- Biomarker talk: Some chase labs (glucose, lipids, CRP); many chase vibes. forum
- Senolytic mouse/human exploratory work: Intermittent dosing papers popular in longevity circles. trial
Doses people talk about
- Common research-inspired intermittent band: dasatinib on the order of ~100 mg/day for 2–3 consecutive days plus quercetin ~1000–1250 mg/day those same days (protocols vary by paper/copy). trialforum
- Frequency: often once monthly or quarterly “hits,” not daily forever. forum
- Framing: “D+Q” senolytic stack from research literature + biohacker copies. trialforum
- Medical reality: dasatinib is a chemo-class kinase inhibitor — self-experiment risk is high. trial
How it may feel
- Pulse and early post-pulse days: Legacy oral discussion includes GI/mood shifts; inspected D+Q accounts describe nausea, fatigue, headache, feverishness or nothing noticeable. Injection-site reactions are not part of the human oral D+Q route. forum
- Pulse days: Often 2–3 consecutive days then long off. forum
- Day 1: Oral logistics or GI symptoms can be more noticeable than any claimed benefit from D+Q; no typical day-one response is established. Injection-site sting is not an effect of oral D+Q. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
Cycles people discuss
- Monthly/quarterly pulses in protocols: community forum
- Common pattern: Community calendars usually copy 2–3 oral on-days followed by weeks or months off. Generic weeks-on/weeks-off wording does not capture these brief pulses; cost and caution also shape informal calendars more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. Combination schedule context: Both components are discussed on the same brief block of on-days, followed by longer gaps; the retained combination notes do not establish one preferred morning or evening slot. forum
- Two components, not one blend clock: Oral dasatinib has a mean terminal half-life of about 3–5 hours; quercetin exposure depends on formulation and analyte context. trial
- Published PK: Where human PK exists it should override forum half-life memes for Dasatinib + Quercetin. trial
More on what it is
- See also: Individual agents may appear separately in catalog. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Dasatinib + Quercetin, not proof it works for you. forum
- What it is: Dasatinib + quercetin “D+Q” senolytic combination from aging research. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Fisetin pulse lore alternatives: community forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Do not DIY oncology drugs lightly: community forum
- Oral pulse effects: Nausea, fatigue, headache or feverish malaise appear in inspected first-person reports; they do not prove senescent-cell ‘die-off.’ forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- Dasatinib toxicities: Serious drug — cytopenias, fluid retention, etc. in medical use. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.